When industry recognition meets strategic growth. Our recent acquisition in Spain marks another step in strengthening Synthon's manufacturing network and supporting our long-term growth ambitions. We're pleased to see this milestone featured by Generics Bulletin (Norstella) highlighting the strategic importance of expanding manufacturing capacity in today's pharmaceutical landscape. Swipe through for the key takeaways, and read the full article here: https://lnkd.in/ea47-4eG #Synthon #Pharmaceuticals #Generics #Manufacturing #LifeSciences #Healthcare
Over ons
Synthon is an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic medicines for patients around the world. Synthon's innovative R&D and proven ability to manufacture and distribute high-quality pharmaceuticals position the company well for the future. We work to develop therapies that address the needs of people worldwide and help improve their health and well-being. Through the provision of high-quality generic medicines, we make treatments more affordable and increase access to important remedies. Currently, our products are approved by regulatory agencies in more than 90 countries and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon’s head office is based in Nijmegen, the Netherlands, and the company has affiliates in eight other countries. Synthon employs around 1,600 staff worldwide. In 2019, the company recorded a turnover of EUR 261 million. We are interested in result-oriented people with a sharp mind and entrepreneurial spirit, who can contribute to our ambition to provide solutions to the healthcare challenges of today and tomorrow. Interested in a new step in your pharma career? We would like to get to know you! For more information, go to www.synthon.com. In case your comment to one of our posts is missing, please check out our guidelines on www.synthon.com/information/comment-missing.
- Website
-
http://www.synthon.com
Externe link voor Synthon
- Branche
- Geneesmiddelenproductie
- Bedrijfsgrootte
- 1.001 - 5.000 medewerkers
- Hoofdkantoor
- Nijmegen
- Type
- Particuliere onderneming
- Opgericht
- 1991
- Specialismen
- Generics, Research, Registration en IP
Locaties
Medewerkers van Synthon
Updates
-
Synthon has announced a strategic expansion of its Sant Boi site in Spain through the acquisition of an adjacent facility, adding 6,000 m² of space to support future development and manufacturing of complex generics. This investment strengthens its European footprint and enhances supply chain resilience to serve patients and partners across the region and globally. The agreement was signed today by Daniel G. Gomez, General Manager Spain, and Anish Mehta, CEO of Synthon. Click here to read the complete press release: https://lnkd.in/ekgb3RRS #Synthon #ComplexGenerics #Enablingaffordablemedicinesglobally #Synthonacquisition
-
-
From early lab setups in Europe to today's global operations, the scale has changed enormously, but our approach to science and quality has stayed the same. We're looking back at some key moments from the Synthon journey: images that show where it all started and how we've grown across regions over time. Each new country was an important step forward, not just in presence, but in reaching more patients with access to affordable medicines. From a strong European foundation to a global footprint, the focus has always been clear: enabling affordable medicines globally. The progress speaks for itself, but the principles behind it remain unchanged. Science. People. Affordable Medicines. #Synthon35Years #ComplexGenerics #Enablingaffordablemedicinesglobally
-
-
35 years ago, one question drove everything: "How do we make complex medicine affordable, everywhere?" Synthon started as an academic spin-off built around that question. Scale was never the starting point. What mattered was understanding the science and making sure it could work beyond a research setting. That meant building things properly. Getting the right processes in place, focusing on quality, and making decisions with the long term in mind. Over time, this shaped how we work. With our partners, it has always been about more than delivering a product. It is about being reliable, consistent, and doing things the right way. Today, Synthon operates globally and reaches millions of patients, but the thinking behind it remains the same. When the science is right from the start, it creates outcomes people can depend on and access that truly makes a difference. #Synthon35Years #ComplexGenerics #Enablingaffordablemedicinesglobally
-
-
Congratulations to BC Partners on this well-deserved recognition! You have been a true source of insight and inspiration, and we’re proud of what we’ve achieved together. At Synthon, our mission is to improve lives around the world by enabling access to affordable medicines in a sustainable way. With the support of strong partners, we continue to expand our reach and impact year after year. Thank you, BC Partners, for your trust and collaboration. We look forward to continuing this journey together, alongside Goldman Sachs Asset Management, as we enter the next phase of growth and patient impact.
We are proud to share that BC Partners has been named winner of the 'Benelux Deal of the Year’ award at Real Deals’ Private Equity Awards 2026, in recognition of our partnership with Synthon. This award is a testament to BC Partners’ approach to building better businesses within sub-sectors we know incredibly well. Real Deals pointed to Synthon’s strong organic growth, capex-led value creation, and strategic execution - including margin improvement, commercial enhancements, and successful international expansion under BC Partners’ ownership. Following the sale of our majority stake in Synthon in December 2024, BC Partners retained a minority stake in the business, reflecting our continued conviction in Synthon’s growth and performance. Congratulations to both the BC Partners and Synthon teams, and everyone involved! You can find out more about our investment in Synthon here: https://lnkd.in/eP3da3Kh
-
-
Do you understand how a brand should feel and know how to bring it to life, taking ownership to ensure every message reflects the strength and consistency of the Synthon brand? Visit our #Synthon website and apply, we look forward to welcoming you to our team.
-
We’re excited to be part of BePharma B2B Pharmaceutical Networking in Mexico City. Our colleagues Koen Steens and Cristina Pardo will be representing Synthon at #BePharma, engaging with partners and exploring new collaboration opportunities across our complex generics portfolio.
-
-
We are looking for a Corporate Director – Business #Applications & #Digital Enablement. In this role, you will shape the strategy and evolution of our enterprise application landscape and partner with senior leaders to drive operational excellence, compliance, and digital innovation. Interested? Visit our website #Synthon and apply!